References
Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet. 1994;344:1398–402.
Schiffman J, Walker E, Ekstrom M, Schulsinger F, Sorensen H, Mednick S. Childhood videotaped social and neuromotor precursors of schizophrenia: a prospective investigation. Am J Psychiatry. 2004;161:2021–7.
Davidson M, Reichenberg A, Rabinowitz J, Weiser M, Kaplan Z, Mark M. Behavioral and intellectual markers for schizophrenia in apparently healthy male adolescents. Am J Psychiatry. 1999;156:1328–35.
Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultze-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. JAMA Psychiatry. 2013;70:107–20.
Formica M, Phillips L, Hartmann J, Yung A, Wood S, Lin A et al. Has improved treatment contributed to the declining rate of transition to psychosis in ultra-high-risk cohorts? Schizophrenia Res. 2020.
Werbeloff N, Drukker M, Dohrenwend BP, Levav I, Yoffe R, van Os J, et al. Self-reported attenuated psychotic symptoms as forerunners of severe mental disorders later in life. Arch Gen Psychiatry. 2012;69:467–75.
Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, et al. At clinical high risk for psychosis: outcome for nonconverters. Am J Psychiatry. 2011;168:800–5.
Perkins DO, Olde Loohuis L, Barbee J, Ford J, Jeffries CD, Addington J, et al. Polygenic risk score contribution to psychosis prediction in a target population of persons at clinical high risk. Am J Psychiatry. 2020;177:155–63.
Chung Y, Allswede D, Addington J, Bearden CE, Cadenhead K, Cornblatt B, et al. Cortical abnormalities in youth at clinical high-risk for psychosis: Findings from the NAPLS2 cohort. Neuroimage Clin. 2019;23:101862.
Johnstone E, Frith C, Crow T, Husband J, Kreel L. Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet. 1976;308:924–26.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr WM has received payment for advisory boards/ fees/speaker fees/performed PANSS training from Teva, Jansen, Dexel and Lundbeck. Dr DM is an employee and owns stock options of Minerva Neurosciences, a Biotech developing CNS drugs.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Weiser, M., Davidson, M. Identifying an elusive target with the help of an unproven technique. Mol Psychiatry 26, 7074–7075 (2021). https://doi.org/10.1038/s41380-021-01213-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41380-021-01213-y
- Springer Nature Limited